紫杉醇联合索拉非尼治疗中晚期肝癌效果分析

Effect analysis of paclitaxel combined with sorafenib in the treatment of advanced liver cancer

目的探究紫杉醇联合索拉非尼治疗中晚期肝癌效果。方法选取2017年1月至2019年2月本院收治的中晚期肝癌患者70例,随机分成对照组和研究组,各35例,对照组给予患者紫杉醇治疗,研究组给予患者紫杉醇联合索拉非尼的治疗,观察两组患者的近期治疗效果和肝功能在治疗前后的改善情况。结果研究组的近期疗效明显优于对照组(P<0.05);研究组的肝功能改善情况优于对照组(P<0.05)。结论紫杉醇联合索拉非尼治疗中晚期肝癌具有显著效果,值得临床推广。

Objective To investigate the effect of paclitaxel combined with sorafenib in the treatment of advanced liver cancer.Methods From January 2017 to February 2019,70 cases of terminal-stage liver cancer patients in our hospital were randomly divided into control group and the study groups,with 35 cases in each group.The control group was given drug therapy,the study groups was given paclitaxel combined sorafenib,observed the therapeutic effects of two groups of patients and improve liver function before and after treatment.Results The short-term efficacy of the study group was significantly better than that of the control group(P<0.05).The improvement of liver function in the research group was better than that in the control group(P<0.05).Conclusion Paclitaxel combined with sorafenib in the treatment of advanced hepatocellular carcinoma has significant effects,and should be promoted in clinical treatment.